Literature DB >> 29936642

Community pharmacists' attitudes and opinions towards supplying clozapine.

Yuh-Lin Gan1, Claire L O'Reilly2.   

Abstract

Background Clozapine is very effective for treatment-resistant schizophrenia, but its use has been limited due to the risk of agranulocytosis. From July 2015, clozapine has been accessible from Australian community pharmacies following regulatory changes, but pharmacists' attitudes towards these changes remain unknown. Objective To explore pharmacists' perspectives and experiences in supplying clozapine. Setting Australian community pharmacists. Methods A cross-sectional study with a mixed methods approach involving two phases. An online survey containing Likert-type and open-response questions was distributed to community pharmacists (n = 134) via ClopineCentral™ (clozapine monitoring system). Participants were then invited to participate in semi-structured telephone interviews (n = 12) regarding clozapine supply. Quantitative data were statistically analysed, while qualitative responses were thematically content-analysed. Main outcome measures Pharmacists' responses to surveys and interviews. Results Community pharmacists were supportive towards supplying clozapine as it increased access for consumers. Better patient-pharmacist relationships and holistic care approach were identified to benefit both consumers and pharmacists. Pharmacists reported to be confident (89.6%), have adequate support (73.1%), knowledge (86.6%) and skills (93.3%) in dispensing clozapine. Training and support received facilitated pharmacists' roles, whereas administrative issues, especially in obtaining valid haematology results, posed challenges. Educational and technical improvements were suggested to improve service provision. Conclusion Community pharmacists welcomed the regulatory changes positively and were confident in supporting consumers taking clozapine. Despite challenges present, benefits and facilitators identified supported the feasibility of this service in community pharmacies. Future research should explore other aspects of clozapine supply, such as attitudes of other stakeholders, to improve current supply systems.

Entities:  

Keywords:  Australia; Clozapine; Community pharmacy; Pharmacy services; Schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29936642     DOI: 10.1007/s11096-018-0676-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  34 in total

1.  New Zealand community pharmacists' views of their roles in meeting medicine-related needs for people with mental illness.

Authors:  Keith Crump; Guobin Boo; Fung Shin Liew; Tracy Olivier; Cecilia So; Jae Yong Sung; Chi Hang Wong; John Shaw; Amanda Wheeler
Journal:  Res Social Adm Pharm       Date:  2010-05-27

Review 2.  Evidence for effective interventions to reduce mental-health-related stigma and discrimination.

Authors:  Graham Thornicroft; Nisha Mehta; Sarah Clement; Sara Evans-Lacko; Mary Doherty; Diana Rose; Mirja Koschorke; Rahul Shidhaye; Claire O'Reilly; Claire Henderson
Journal:  Lancet       Date:  2015-09-22       Impact factor: 79.321

3.  Privacy and confidentiality: perspectives of mental health consumers and carers in pharmacy settings.

Authors:  Hendrika Laetitia Hattingh; Kathy Knox; Jasmina Fejzic; Denise McConnell; Jane L Fowler; Amary Mey; Fiona Kelly; Amanda J Wheeler
Journal:  Int J Pharm Pract       Date:  2014-04-25

4.  Clozapine in the community: Improved access or risky free-for-all?

Authors:  Karl Winckel; Dan Siskind; Sam Hollingworth; Gail Robinson; Scott Mitchell; Daniel Varghese; Lesley Smith; Amanda J Wheeler
Journal:  Aust N Z J Psychiatry       Date:  2015-06-22       Impact factor: 5.744

5.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.

Authors:  Cherrie Galletly; David Castle; Frances Dark; Verity Humberstone; Assen Jablensky; Eóin Killackey; Jayashri Kulkarni; Patrick McGorry; Olav Nielssen; Nga Tran
Journal:  Aust N Z J Psychiatry       Date:  2016-05       Impact factor: 5.744

6.  Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey.

Authors:  Edward Kim; Shaloo Gupta; Susan Bolge; Chi-Chang Chen; Richard Whitehead; John A Bates
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

7.  Attitudes of pharmacists toward mental illness and providing pharmaceutical care to the mentally ill.

Authors:  Marshall E Cates; Amber R Burton; Thomas W Woolley
Journal:  Ann Pharmacother       Date:  2005-06-21       Impact factor: 3.154

Review 8.  Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.

Authors:  G Remington; J Lee; O Agid; H Takeuchi; G Foussias; M Hahn; G Fervaha; L Burton; V Powell
Journal:  Expert Opin Drug Saf       Date:  2016-06-01       Impact factor: 4.250

9.  Consumer access to clozapine in Australia: how does this compare to New Zealand and the United Kingdom?

Authors:  Sally-Anne Knowles; Sara S Mcmillan; Amanda J Wheeler
Journal:  Pharm Pract (Granada)       Date:  2016-06-15

Review 10.  Clozapine: a review of clinical practice guidelines and prescribing trends.

Authors:  Stephanie Warnez; Silvia Alessi-Severini
Journal:  BMC Psychiatry       Date:  2014-04-07       Impact factor: 3.630

View more
  1 in total

1.  Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators.

Authors:  Bethany Wilson; Sara S McMillan; Amanda J Wheeler
Journal:  J Pharm Policy Pract       Date:  2019-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.